)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Pharming Group
Pharming Group (PHARM) investor relations material
Pharming Group Corporate presentation summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate presentation summary1 Aug, 2026
Strategic vision and commercial foundation
Aims to become a leading global rare disease company with a diverse portfolio and strong presence in large markets.
Leverages proven clinical development, supply chain, and commercial infrastructure.
RUCONEST and Joenja serve as commercial cornerstones, providing durable cash flow and growth momentum.
Product portfolio and pipeline highlights
RUCONEST is approved for acute hereditary angioedema (HAE), showing rapid, reliable attack resolution and a resilient patient base.
Joenja (leniolisib) is approved for APDS, with ongoing expansion into pediatric and international markets and Phase II studies in PIDs/CVID.
Napazimone (KL1333) is in pivotal trials for mtDNA mitochondrial disease, with positive interim analysis and >$1B revenue potential.
RUCONEST performance and clinical data
97% of acute HAE attacks resolved with one dose; median time to complete resolution is 4.5 hours.
Demonstrates significantly faster attack resolution compared to sebetralstat, with 93.4% of attacks resolved within 24 hours.
Q2 2026 revenue was $72.3M, down 10% YoY but up 24% sequentially, with stabilization and growth expected by year-end.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Pharming Group
- Joenja revenue rose 40% as RUCONEST stabilized, prompting revised 2026 guidance and global expansion.PHARM
Q2 2026 - Joenja® and pipeline advances fuel growth as RUCONEST® remains a stable cash engine.PHARMJefferies Global Healthcare Conference 2026
- Shareholders approved all proposals amid strong financial growth and rare disease expansion plans.PHARMAGM 2026
- Joenja®'s 34% growth offsets RUCONEST®'s decline, supporting reaffirmed 2026 guidance.PHARMQ1 2026
- Strong financial growth, pipeline milestones, and regulatory progress drive rare disease leadership.PHARM25th Annual Needham Virtual Healthcare Conference
- Acquisition adds KL1333, a late-stage rare disease therapy, accelerating growth and value.PHARMM&A Announcement
- Q3 2024 revenues up 12% to $74.8M, driven by RUCONEST and Joenja growth; 2024 outlook reaffirmed.PHARMQ3 2024
- Strong revenue growth, pipeline progress, and board changes marked the 2025 AGM.PHARMAGM 2025
- Q1 2025 revenue up 42%, guidance raised, and pipeline expanded with Abliva acquisition.PHARMQ1 2025
Next Pharming Group earnings date
Q3 20265 Nov, 2026
Pharming Group
Next Pharming Group earnings date
Q3 20265 Nov, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage